A Study to Compare to PK Characteristics and Safety Profiles Between AD-227 and Co-administration of AD-227A and AD-227B

Launched by ADDPHARMA INC. · Mar 13, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new medication called AD-227 to see how it behaves in the body—specifically, how it is absorbed, distributed, and eliminated. The main goal is to compare the effects of AD-227 alone to a combination of two other medications, AD-227A and AD-227B, in healthy adults. This research is important for understanding how well AD-227 works and how safe it is for people with primary hypertension, which is high blood pressure.

To join this study, participants must be at least 19 years old, weigh at least 50 kg (or 45 kg for females), and have a body mass index (BMI) between 18.0 and 30.0. Individuals who have taken another investigational drug in the past six months or meet certain other criteria may not be eligible. If you participate, you'll undergo some health assessments and receive the study medication, with careful monitoring to ensure your safety. Overall, this trial aims to provide valuable information that could help improve treatment options for high blood pressure.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Body weight equal to or greater than 50kg (Female 45kg) and Body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit
• • The Age equal to or greater than 19 in healthy volunteers at the time of screening visit
• Exclusion Criteria:
• • Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration
• • Other exclusions applied